Xiu et al. [91] reported that CMS increased serum TNF-α production and serum concentration of IL-6 both in tumor-bearing and non-tumor-bearing rats, although Grippo et al. [87] could not find changes of IL-6 in brain and serum of CMS-treated animals. The gene discussed is TNF; the disease is neoplasm.